MétaCan
Menu
Back to cohort
Record W3197361064 · doi:10.1111/bjh.17807

<i>BCR–ABL1</i> transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase

2021· article· en· W3197361064 on OpenAlexafffund
Dennis Dong Hwan Kim, Taehyung Simon Kim, Eshetu G. Atenafu, Igor Novitzky‐Basso, Donna L. Forrest, Isabelle Bence‐Bruckler, Lynn Savoie, Lambert Busque, Mary‐Margaret Keating, Robert Delage, Anargyros Xenocostas, Elena Liew, Kristjan Paulson, Tracy Stockley, Pierre Laneuville, Jeffrey H. Lipton, Suzanne Kamel‐Reid, Brian Leber

Bibliographic record

VenueBritish Journal of Haematology · 2021
Typearticle
Languageen
FieldMedicine
TopicChronic Myeloid Leukemia Treatments
Canadian institutionsMcMaster UniversityToronto General HospitalUniversity of AlbertaLondon Health Sciences CentreHôpital de l'Enfant-JésusQueen Elizabeth II Health Sciences CentreDalhousie UniversityUniversité de MontréalHôpital Maisonneuve-RosemontPrincess Margaret Cancer CentreVancouver General HospitalUniversity of CalgaryBC Cancer AgencyAlberta Health ServicesMcGill University Health CentreUniversity of OttawaCalgary Laboratory ServicesCancerCare ManitobaOttawa HospitalUniversity Health NetworkWestern UniversityUniversity of TorontoUniversity of British Columbia
FundersBristol-Myers Squibb CanadaPrincess Margaret Cancer FoundationNovartis
KeywordsDiscontinuationImatinibChronic myeloid leukaemiaInternal medicineMedicineDoubling timeImatinib mesylateGastroenterologybreakpoint cluster regionOncologyImmunologyMyeloid leukemiaBiologyCellGeneticsReceptor

Abstract

fetched live from OpenAlex

The doubling time (DT) of the BCR-ABL1 quantitative polymerase chain reaction (qPCR) transcript level reflects the re-growing fraction of leukaemic cells after discontinuation of tyrosine kinase inhibitor (TKI). The present study analyzed monthly DT within six months after imatinib discontinuation in 131 patients. Monthly DT was calculated as x = ln(2)/K, where x is the DT and K is the fold BCR-ABL1 change from the previous value divided by the number of days between each measurement. The optimal DT value was determined as 12·75 days at two months using a recursive partitioning method. The patients were stratified into three groups: the high-risk group (DT<12·75 days but >0, with rapidly proliferating chronic myeloid leukaemia (CML) cells; n = 26) showed the lowest molecular relapse-free survival (mRFS) of 7·7% at 12 months, compared to 53·6% in the intermediate-risk group (DT≥12·75 days, with slowly proliferating CML cells; n = 16) or 90·0% in the low-risk group (DT≤0, i.e., without proliferating CML cells; n = 71; P < 0·001). Monthly assessment of DT helps identify high-risk patients for treatment-free remission failure with an imminent risk of molecular recurrence, and to define low-risk patients who can be spared the frequent monitoring of monthly molecular tests.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.296
Teacher spread0.282 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueBritish Journal of HaematologySame topicChronic Myeloid Leukemia TreatmentsFrench-language works237,207